Northern Trust Corp Has $182.85 Million Holdings in Hologic, Inc. $HOLX

Key Points

• Northern Trust Corp reduced its stake in Hologic, Inc. by 6.0%, now holding approximately 1.33% of the company with a value of $182.85 million after selling 187,300 shares.
• Hologic stock recently opened at $67.17 and has a market cap of $14.94 billion, with analysts giving it a consensus rating of "Moderate Buy" and an average target price of $78.00.
• During its last quarterly earnings report, Hologic reported $1.08 earnings per share and revenue of $1.02 billion, exceeding analysts' expectations.

Northern Trust Corp cut its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 6.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,960,120 shares of the medical equipment provider's stock after selling 187,300 shares during the period. Northern Trust Corp owned approximately 1.33% of Hologic worth $182,847,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT acquired a new position in Hologic in the 1st quarter worth $34,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Hologic during the 1st quarter worth about $42,000. Raiffeisen Bank International AG acquired a new position in shares of Hologic during the 4th quarter worth about $49,000. Allworth Financial LP boosted its stake in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after buying an additional 216 shares during the last quarter. Finally, Larson Financial Group LLC boosted its stake in shares of Hologic by 6,016.7% during the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after buying an additional 722 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HOLX. Evercore ISI increased their price objective on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Argus upgraded shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a research note on Monday. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their price objective for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. Raymond James Financial restated an "outperform" rating and set a $71.00 price objective (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Finally, Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $78.00.

Hologic Stock Down 2.3%

Hologic stock opened at $67.17 on Friday. The stock has a market cap of $14.94 billion, a P/E ratio of 27.87, a P/E/G ratio of 2.49 and a beta of 0.49. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The company's 50-day moving average price is $65.83 and its two-hundred day moving average price is $62.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business's revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.